2,242 results on '"Berdel, Wolfgang E"'
Search Results
152. Characteristics and Outcome of Elderly Patients (>55 years) with Acute Lymphoblastic Leukemia
153. Tumor‐Cell‐Specific Targeting of Ibrutinib: Introducing Electrostatic Antibody‐Inhibitor Conjugates (AiCs)
154. Allogeneic Hematopoietic Cell Transplantation in Patients ≤ 60 Years with Intermediate-Risk Acute Myeloid Leukemia in First Remission - Results of the Randomized Etal-1 Trial-
155. A Phase I Trial of the Antibody-Cytokine Fusion Protein F16IL2 in Combination with Anti-CD33 Immunotherapy for Posttransplant AML Relapse
156. Quality of Life and Life Satisfaction in AML Long-Term Survivors: Primary Results of the AMLCG-Survivorship Study
157. High Prevalence of CHF and Diabetes in AML Long-Term Survivors - a Patient Forever?
158. Characteristics and Outcome of Elderly Patients (> 55 Years) with Acute Lymphoblastic Leukemia (ALL)
159. Multi-Dimensional Analysis of Adult Acute Myeloid Leukemia (AML) Landscape Cross-Continents Reveals Age Associated Trends in Mutations and Outcomes
160. Final Induction Therapy Results of an Open Label Phase II Study Using Inotuzumab Ozogamicin for Induction Therapy, Followed By a Conventional Chemotherapy Based Consolidation and Maintenance Therapy in Patients Aged 56 Years and Older with Acute B-Lymphoblastic Leukemia (INITIAL-1 trial)
161. Resilience in patients after allogeneic stem cell transplantation
162. Impact of preexisting chronic kidney disease on acute and long-term outcome of critically ill patients on a medical intensive care unit
163. Non-invasive monitoring of tumor-vessel infarction by retargeted truncated tissue factor tTF–NGR using multi-modal imaging
164. TP53 mutation in patients with high-risk acute myeloid leukaemia treated with allogeneic haematopoietic stem cell transplantation
165. Profiling of histone H3 lysine 9 trimethylation levels predicts transcription factor activity and survival in acute myeloid leukemia
166. Pim2 cooperates with PML-RARα to induce acute myeloid leukemia in a bone marrow transplantation model
167. BCR-ABL enhances differentiation of long-term repopulating hematopoietic stem cells
168. An open-label, Phase I study of cediranib (RECENTIN™) in patients with acute myeloid leukemia
169. Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes
170. Tissue-factor fusion proteins induce occlusion of tumor vessels
171. Remissions of different quality following rituximab, tocilizumab and rituximab, and allogeneic stem cell transplantation in a patient with severe idiopathic multicentric Castleman’s disease
172. D DX41-Low Expression Mimics Germline DDX41-Phenotype in Acute Myeloid Leukemia
173. E3 ligase–defective Cbl mutants lead to a generalized mastocytosis and myeloproliferative disease
174. Epigenetic dysregulation of KCa3.1 channels induces poor prognosis in lung cancer
175. Infarction of tumor vessels by NGR-peptide–directed targeting of tissue factor: experimental results and first-in-man experience
176. Dose-dense induction with sequential high-dose cytarabine and mitoxantone (S-HAM) and pegfilgrastim results in a high efficacy and a short duration of critical neutropenia in de novo acute myeloid leukemia: a pilot study of the AMLCG
177. Experimental Chemotherapy of Radiation Injury with Synthetic Lysophospholipid Analogs in Mice
178. DexaBEAM versus ICE salvage regimen prior to autologous transplantation for relapsed or refractory aggressive peripheral T cell lymphoma: a retrospective evaluation of parallel patient cohorts of one center
179. Acute leukemias of ambiguous lineage in adults: molecular and clinical characterization
180. Outcome of elderly patients with acute promyelocytic leukemia: results of the German Acute Myeloid Leukemia Cooperative Group
181. Integrated RNAi Screening Identifies The NEDDylation Pathway As A Synergistic Partner of Azacytidine In Acute Myeloid Leukemia
182. Targeting Tissue Factor to Tumor Vasculature to Induce Tumor Infarction
183. Dose escalation and expansion phase I studies with the tumour-targeting antibody-tumour necrosis factor fusion protein L19TNF plus doxorubicin in patients with advanced tumours, including sarcomas
184. Hotspot DNMT3A mutations in Clonal Hematopoiesis and Acute Myeloid Leukemia sensitize cells to Azacytidine via viral mimicry response
185. Introduction
186. Loss-of-function mutations of bcor are an independent marker of adverse outcomes in intensively treated patients with acute myeloid leukemia
187. POEMS syndrome treated with melphalan high-dose therapy and autologous blood stem cell transplantation: a single-institution experience
188. Adjuvant therapy for resectable high-risk soft tissue sarcoma: feasibility and efficacy of a sandwich chemoradiotherapy strategy
189. Age-dependent frequencies of NPM1 mutations and FLT3-ITD in patients with normal karyotype AML (NK-AML)
190. C/EBP ζ mediates nicotinamide-enhanced clearance of Staphylococcus aureus in mice
191. Visceral leishmaniasis clinically mimicking lymphoma
192. Remission and Survival after Single Versus Double Induction with 7+3 for Newly Diagnosed Acute Myeloid Leukemia: Results from the Planned Interim Analysis of Randomized Controlled SAL-Daunodouble Trial
193. An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia
194. Clinical molecular imaging in intestinal graft-versus-host disease: mapping of disease activity, prediction, and monitoring of treatment efficiency by positron emission tomography
195. Chromatin modifications induced by PML-RARα repress critical targets in leukemogenesis as analyzed by ChIP-Chip
196. Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non-small-cell lung cancer
197. Expression of VEGF-C and its receptor VEGFR-3 in the bone marrow of patients with acute myeloid leukaemia
198. Nicotinamide treatment ameliorates the course of experimental colitis mediated by enhanced neutrophil-specific antibacterial clearance
199. DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed myeloma
200. Prognostic factors for acute myeloid leukaemia in adults – biological significance and clinical use
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.